14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
ICCC vs CSBR: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Immucell Corp (ICCC) is the stronger overall head-to-head candidate over Champions Oncology, Inc. (CSBR) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). ICCC carries a Unified Composite Score of 43.8/100 (HOLD) at $11.42 (N/M Forward P/E, 15.2% operating margin), whereas CSBR carries 44.4/100 (HOLD) at $4.68 (46.8x Forward P/E, -1.5% operating margin).
Composite vs. Pillar Nuance: While CSBR currently prints a higher short-term Unified Composite Score (44.4/100 HOLD vs. ICCC 43.8/100 HOLD), ICCC captures the overall institutional head-to-head verdict (6–4 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (15.2% vs. -1.5% operating margin) and revenue trajectory (+11.5% vs. +8.8% YoY).
Technical & Structure Timing Caution: ICCC trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 67.5); meanwhile CSBR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 42.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ICCC vs CSBR. Trailing 12-month operating profitability (ICCC 15.2% vs CSBR -1.5%) and valuation multiples (ICCC N/M vs CSBR 46.8x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $65.5M market capitalization and -1.5% operating margin.
OpEx & R&D Reinvestment51.3% of Rev ($31M)
90D Engineering Disclosures0 Published
Investor FAQ ICCC vs CSBR Key Questions & Quantitative Answers
As of Nov 16, 2026, Immucell Corp (ICCC) is the stronger overall head-to-head candidate over Champions Oncology, Inc. (CSBR) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). ICCC carries a Unified Composite Score of 43.8/100 (HOLD) at $11.42 (N/M Forward P/E, 15.2% operating margin), whereas CSBR carries 44.4/100 (HOLD) at $4.68 (46.8x Forward P/E, -1.5% operating margin). Composite vs. Pillar Nuance: While CSBR currently prints a higher short-term Unified Composite Score (44.4/100 HOLD vs. ICCC 43.8/100 HOLD), ICCC captures the overall institutional head-to-head verdict (6–4 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (15.2% vs. -1.5% operating margin) and revenue trajectory (+11.5% vs. +8.8% YoY). Technical & Structure Timing Caution: ICCC trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 67.5); meanwhile CSBR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 42.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
ICCC leads the Growth & Scale pillar: ICCC posts +11.5% YoY revenue growth and +259.9% YoY earnings growth on $67M TTM revenue (40.3% gross margin, 15.2% operating margin), compared with CSBR at +8.8% YoY revenue growth and -61.1% YoY earnings growth on $61M TTM revenue (49.8% gross margin, -1.5% operating margin). On trailing 12-month operating scale, ICCC generates $67M in USD-normalized revenue versus $61M for CSBR. In operating R&D and SG&A reinvestment, ICCC deploys 25.1% of Rev ($17M) (0 90-day corporate R&D disclosures) versus 51.3% of Rev ($31M) (0 disclosures) for CSBR.
CSBR screens cheaper on headline valuation multiples. ICCC trades at N/M Forward P/E, 56.6x Trailing P/E, N/M PEG, and 1.6x EV/Revenue (11.0% FCF margin), whereas CSBR trades at 46.8x Forward P/E, 22.9x Trailing P/E, N/M PEG, and 1.1x EV/Revenue (0.7% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ICCC (2.6% ROE) versus CSBR (-28.4% ROE) capital efficiency.
In options market volatility and institutional positioning, ICCC carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.24β · 46% Vol realized risk). By comparison, CSBR carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.36β · 24% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.